Unapproved dermatologic indications for H2 receptor antagonists, cromolyn sodium, and ketotifen.
Paquette
D
D
Department of Dermatology, University of Connecticut Health Center, Farmington 06030, USA.
Rothe
M J
MJ
D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D002927:Cimetidine / Q000627:therapeutic use; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D017277:Drug Approval; D004363:Drug Utilization; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007665:Ketotifen / Q000627:therapeutic use*; D011899:Ranitidine / Q000627:therapeutic use; D012871:Skin Diseases / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D018927:Anti-Asthmatic Agents; D003879:Dermatologic Agents; D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D002927:Cimetidine; D011899:Ranitidine; D004205:Cromolyn Sodium; D007665:Ketotifen